What we do

AmebaGone Inc. will solve one of the 21st century’s most compelling problems -- that of growing antibiotic resistance alongside a dwindling supply of effective antimicrobial products.  Antibiotic resistance is a worldwide problem that manifests itself in agriculture, medicine and industry. And while the threat of infectious disease is intensifying, the discovery of new antibiotics has slowed dramatically. Pharmaceutical companies have largely abandoned the discovery of new antibiotics, despite the liklihood of an impending health crisis.

AmebaGone 's team is stepping boldly in to explore new antimicrobial strategies, integrating its proprietary technology reliant on the use of benign, free-living phagocytes to combat bacterial pathogens in crops, animals and humans.  Importantly, AmebaGone's proprietary technology can combat biofilm-enmeshed pathogens, which antibiotics cannot.    

Funding support provided by the National Science Foundation and the National Institutes of Health. Also supported by the Wisconsin Economic Development Corporation (WEDC) and the Madison Development Corp. (MDC).

  
Support also provided by the CleanTech Open and by LARTA Institute